In summary, this study provides evidence that a strategy of treating patients with obesity and T2DM-Ins with SG or RYGB is associated with a significant incidence of diabetes remission and a high incidence of cessation of insulin therapy. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.